Employing the known CHI3L1 inhibitors,K284 and G721-0282, as scaffolds, our objective is to identify novelcompounds capable of inhibiting CHI3L1 that can be repurposed in theclinical setting, thereby offering promising therapeutic approachesfor inflammatory diseases like MS. Here, CHI3L1 is linked to myeloid sarcoma.